NIFTY 50 Close 29 Oct

Q2 FY27 earnings results

Jul–Sep 2026 quarter · revenue and profit against the same quarter last year (YoY) and the quarter before (QoQ). INR crore, consolidated where filed.

385 companies have reported Jul–Sep 2026 and 937 more have a results date ahead. 73% grew profit from a year ago; the typical company's sales grew +20.9% and profit +21.2%. Strongest sector: Telecommunication (+83.6%); weakest: Oil Gas & Consumable Fuels (-0.4%).

Declared
385/ 1322
29% of scheduled reporters
Profit breadth
73%/27%
grew / declined · 339 comparable
Median sales growth
+20.9%
year on year, all reporters
Median profit growth
+21.2%
year on year, all reporters
Operating margin
211/163
expanded / shrank vs a year ago
Strongest / weakest

Telecommunication +83.6%

Oil Gas & Consumable Fuels -0.4%

median profit growth, 5+ reporters
1–9 of 9
CompanyRevenue (₹ Cr)Net profit (₹ Cr)Per shareQuarter
SymbolSectorReportedYoYQoQReportedYoYQoQEPS (₹)Verdict8Q profit
DRREDDYDr. Reddy's Laboratories LimitedHealthcare8,698-1.5%+7.4%913-31.7%+109.4%11.08ShrinkingQ4 FY25 1,587 · Q1 FY26 1,410 · Q2 FY26 1,337 · Q3 FY26 1,190 · Q4 FY26 221 · Q1 FY27 436 · Q2 FY27 913
CIPLACipla LimitedHealthcare7,404-2.4%+4.0%852-37.0%+8.4%10.86ShrinkingQ4 FY25 1,214 · Q1 FY26 1,292 · Q2 FY26 1,353 · Q3 FY26 674 · Q4 FY26 543 · Q1 FY27 786 · Q2 FY27 852
TORNTPHARMTorrent Pharmaceuticals LimitedHealthcare4,979+50.8%+1.2%534-9.6%-5.7%14.04MixedQ4 FY25 498 · Q1 FY26 548 · Q2 FY26 591 · Q3 FY26 635 · Q4 FY26 364 · Q1 FY27 566 · Q2 FY27 534
MANKINDMankind Pharma LimitedHealthcare4,338+17.3%+7.6%716+37.7%+24.7%17.23GrowingQ4 FY25 425 · Q1 FY26 445 · Q2 FY26 520 · Q3 FY26 414 · Q4 FY26 559 · Q1 FY27 574 · Q2 FY27 716
ERISEris Lifesciences LimitedHealthcare892+12.6%+2.2%187+39.6%+30.8%13.25GrowingQ4 FY25 102 · Q1 FY26 125 · Q2 FY26 134 · Q3 FY26 109 · Q4 FY26 279 · Q1 FY27 143 · Q2 FY27 187
SYNGENESyngene International LimitedHealthcare833-8.6%+13.2%32-52.2%n/a0.80ShrinkingQ4 FY25 183 · Q1 FY26 87 · Q2 FY26 67 · Q3 FY26 15 · Q4 FY26 148 · Q1 FY27 -9 · Q2 FY27 32
ONESOURCEOnesource Specialty Pharma LimitedHealthcare516+37.2%+14.9%57+470.0%+128.0%5.01GrowingQ4 FY25 98 · Q1 FY26 0 · Q2 FY26 10 · Q3 FY26 -89 · Q4 FY26 5 · Q1 FY27 25 · Q2 FY27 57
ACUTAASAcutaas Chemicals LimitedHealthcare437+42.8%+32.4%123+70.8%+64.0%15.29GrowingQ4 FY25 63 · Q1 FY26 44 · Q2 FY26 72 · Q3 FY26 106 · Q4 FY26 134 · Q1 FY27 75 · Q2 FY27 123
CONCORDBIOConcord Biotech LimitedHealthcare312+26.3%+19.5%76+20.6%+24.6%7.24GrowingQ4 FY25 142 · Q1 FY26 43 · Q2 FY26 63 · Q3 FY26 68 · Q4 FY26 90 · Q1 FY27 61 · Q2 FY27 76

Verdict: Growing sales and profit both up on a year ago · Shrinking both down · Mixed one up, one down · Back to profit a profit after a loss a year ago · Loss a loss this quarter. "n/a" means a year-ago or previous figure isn't available, or it was a loss, so a percentage would mislead.